ImmunoGen, Inc.
Oct 28, 2010
PDF

ImmunoGen, Inc. Reports First Quarter Fiscal Year 2011 Financial Results

- Advancing and Expanding Product Programs While Maintaining Strong Liquidity -

WALTHAM, Mass., Oct 28, 2010 (BUSINESS WIRE) --

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended September 30, 2010 - the first quarter of the Company's 2011 fiscal year (1QFY11).

"The breadth of our recent achievements illustrates ImmunoGen's strong position as a company," says Daniel Junius, President and CEO. "The clinical data for IMGN901 and T-DM1 plus our new collaboration with Novartis - all announced earlier this month - demonstrate our forward momentum. We expect at least five presentations of new clinical data in the next two months alone, and we're on track for as many as 12 compounds, partnered and proprietary, to be in the clinic by the end of 2011. Of these clinical-stage compounds, several are expected to advance into Phase II testing during the coming year. We believe our innovative and valuable technology, promising product candidates, productive partnerships and strong balance sheet provide us with a solid foundation for value generation in our 2011 fiscal year and beyond."

Our Proprietary Product Candidates - Highlights

IMGN901 (lorvotuzumab mertansine) - in clinical testing for treatment of CD56+ solid tumors and multiple myeloma.

IMGN388 - in clinical testing for treatment of solid tumors.

IMGN529 - in preclinical development for types of liquid tumors.

IMGN853 - in preclinical development for types of solid tumors.

Partner Product Candidates - Highlights

Trastuzumab-DM1 (T-DM1) - in global development by Roche for treatment of HER2+ breast cancer (BC).

SAR3419, SAR650984, and SAR566658 - in development by sanofi-aventis as a result of a previous research collaboration with ImmunoGen.

Other partner compounds

Financial Results

ImmunoGen reported a net loss of $12.9 million, or $0.19 per basic and diluted share, for 1QFY11 compared to a net loss of $12.4 million, or $0.22 per basic and diluted share, for the same period last year.

Revenues were $3.4 million for 1QFY11, compared to $3.1 million for the same period last year. Both periods include $1.8 million of license and milestone fees. Revenues in 1QFY11 also include $1.5 million of research and development support fees and $0.1 million of clinical material reimbursement, compared to $0.8 million and $0.5 million, respectively, for the same quarter last year.

Operating expenses for 1QFY11 were $16.8 million, compared to $15.8 million in the same period last year. Operating expenses in 1QFY11 include research and development expenses of $13.4 million, compared to $12.2 million in 1QFY10, and general and administrative expenses of $3.4 million, compared to $3.6 million in 1QFY10.

Other income, net, consisting primarily of gains recognized on sales of investments, gains recognized on forward contracts, and interest income, was $0.5 million in 1QFY11, compared to $0.1 million for the same period last year.

ImmunoGen had approximately $94.9 million in cash and marketable securities as of September 30, 2010, compared with $110.3 million as of June 30, 2010, and had no debt outstanding in either period. During the first three months of fiscal 2011, cash used in operations was $15.3 million, compared to $11.4 million during the same period in fiscal 2010. Capital expenditures were $0.3 and $0.6 million for the first three months of fiscal years 2011 and 2010, respectively.

Financial Guidance

ImmunoGen expects its net loss for its fiscal year ending June 30, 2011 to be between $60-64 million, its cash used in operations to be between $0-4 million, and its capital expenditures to be between $2-3 million. Cash and marketable securities at June 30, 2011 are anticipated to be between $106-110 million. Reflected in this guidance is the collaboration established in October 2010 with Novartis.

"These results and our financial guidance reflect our commitment to aggressively advancing our proprietary compounds to value-inflection points and using business development as a way to advance the technology while generating non-dilutive cash," commented Gregory Perry, Senior Vice President and CFO.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies and potent cancer-cell killing agents. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are currently seven TAP compounds in the clinic, with a wealth of clinical data reported with the technology. ImmunoGen's collaborative partners include Amgen, Bayer Schering Pharma, Biogen Idec, Biotest, Genentech (a member of the Roche Group), Novartis, and sanofi-aventis. The most advanced compound using ImmunoGen's TAP technology, T-DM1, is in Phase III testing through the Company's collaboration with Genentech. More information about ImmunoGen can be found at www.immunogen.com.

Revlimid® is a registered trademark of Celgene Corporation.

This press release includes forward-looking statements based on management's current expectations. These statements include, but are not limited to, ImmunoGen's expectations related to: the Company's net loss, cash used in operations and capital expenditures in its 2011 fiscal year; its cash and marketable securities as of June 30, 2011; the occurrence, timing and outcome of potential pre-clinical, clinical and regulatory events related to the Company's and its collaboration partners' product programs; and the presentation of preclinical and clinical data on the Company's and collaboration partners' product candidates. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Various factors could cause ImmunoGen's actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the timing and outcome of ImmunoGen's and the Company's collaboration partners' research and clinical development processes; the difficulties inherent in the development of novel pharmaceuticals, including uncertainties as to the timing, expense and results of preclinical studies, clinical trials and regulatory processes; ImmunoGen's ability to financially support its product programs; ImmunoGen's dependence on collaborative partners; industry merger and acquisition activity; and other factors more fully described in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June 30, 2010 and other reports filed with the Securities and Exchange Commission.

                     
SELECTED FINANCIAL INFORMATION
(in thousands, except per share amounts)
                     
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
                     
        September 30,   June 30,
        2010   2010
ASSETS                    
                     
Cash, cash equivalents and marketable securities       $ 94,942     $ 110,298  
Other assets         25,817       26,910  
                     
Total assets       $ 120,759     $ 137,208  
                     
LIABILITIES AND SHAREHOLDERS' EQUITY                    
                     
Current liabilities       $ 9,706     $ 13,822  
Long-term portion of deferred revenue and other long-term liabilities         20,532       21,338  
Shareholders' equity         90,521       102,048  
                     
Total liabilities and shareholders' equity       $ 120,759     $ 137,208  
                     
                     
                     
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
        Three Months Ended
        September 30,
        2010   2009
                     
Revenues:                    
License and milestone fees       $ 1,810     $ 1,831  
Research and development support         1,495       782  
Clinical materials reimbursement         106       486  
                     
                     
Total revenues         3,411       3,099  
                     
Expenses:                    
Research and development         13,425       12,188  
General and administrative         3,364       3,592  
                     
Total operating expenses         16,789       15,780  
                     
Loss from operations         (13,378 )     (12,681 )
                     
Other income, net         490       144  
                     
Loss before taxes         (12,888 )     (12,537 )
                     
(Benefit)/provision for income taxes         -       (162 )
                     
Net loss       $ (12,888 )   $ (12,375 )
                     
Net loss per common share, basic and diluted       $ (0.19 )   $ (0.22 )
                     
                     
Average common shares outstanding, basic and diluted         67,944       57,032  

SOURCE: ImmunoGen, Inc.

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For Media:
The Yates Network
Adriana Jenkins, 617-710-8350